

The impact of rare disease



7000+

rare diseases, many life threatening.

3.5 million

affected in the UK alone



70%

of cases affect children.

95%

lack effective treatment.



What is ARDAT?

Founded in 2019, funded by Innovative Health Initiative

A consortium of 32 partners from academia, industry & SMEs worldwide

Our mission is to advance our collective knowledge about ATMPs and accelerate the development of new treatments for rare diseases.

Aims:

Understand immune responses to ATMPs

Advance AAV delivery technology

Create a shared research biobank

Harmonise global regulations



Achievements:

Developed 3D liver & CNS immune models

Improved AAV efficiency & gene delivery

Established the ARDAT Biobank (REC approved)

Engaged with key global regulators

We've also...



Released 13 publications, several others under review



Progressed a new gene therapy



Listened to those with lived experience



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 945473. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA [Pfizer and Bayer].

Any information on this communication solely reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.

IHI website: www.ih.europa.eu

Send feedback to Rachel Waller, ARDAT Project Manager:

r.waller@sheffield.ac.uk



innovative
medicines
initiative

